Lyra Therapeutics (LYRA) Invested Capital (2021 - 2025)
Historic Invested Capital for Lyra Therapeutics (LYRA) over the last 5 years, with Q3 2025 value amounting to -$4.3 million.
- Lyra Therapeutics' Invested Capital fell 12099.03% to -$4.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$4.3 million, marking a year-over-year decrease of 12099.03%. This contributed to the annual value of $11.6 million for FY2024, which is 8703.42% down from last year.
- Latest data reveals that Lyra Therapeutics reported Invested Capital of -$4.3 million as of Q3 2025, which was down 12099.03% from $1.6 million recorded in Q2 2025.
- In the past 5 years, Lyra Therapeutics' Invested Capital registered a high of $106.2 million during Q2 2022, and its lowest value of -$4.3 million during Q3 2025.
- For the 5-year period, Lyra Therapeutics' Invested Capital averaged around $52.1 million, with its median value being $57.5 million (2021).
- In the last 5 years, Lyra Therapeutics' Invested Capital soared by 18417.68% in 2023 and then crashed by 12099.03% in 2025.
- Quarter analysis of 5 years shows Lyra Therapeutics' Invested Capital stood at $34.3 million in 2021, then surged by 135.32% to $80.8 million in 2022, then grew by 10.73% to $89.4 million in 2023, then crashed by 87.03% to $11.6 million in 2024, then crashed by 137.33% to -$4.3 million in 2025.
- Its Invested Capital stands at -$4.3 million for Q3 2025, versus $1.6 million for Q2 2025 and $3.9 million for Q1 2025.